Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)

Covid-19 Clinical Trial

— Covid-19  

Official title:

Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia: A Single Center Experience in Turkey

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04379310
• Other study ID #: 20200504441
• Status: Completed
• Start date: May 1, 2020
• Est. completion date: May 8, 2020

Study information

• Verified date: June 2020
• Source: Nisantasi University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively and analyze their clinical and demographic features on admission in regard to their medications used for chronic diseases regularly.

Description:

Covid-19 infections demonstrated a pandemic spread after January 2020 and their associations with patient characteristics and comorbidities are intensely studied. Investigators also want to find out potential relations between major medications taken for chronic diseases and clinical parameters of patients with Covid-19 pneumonia.

For the study, investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 (the date at which the first case of Covid-19 in Turkey officially declared) and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively. All of the demographic features, complaints on admission, reports of computed tomography (CT) scans of the chest without intravenous contrast issued by the staff radiologist, c-reactive protein (CRP) and complete blood count (CBC) values on admission will be recorded retrospectively. Their polymerase chain reaction (PCR) test results will be derived from the hospital records based on public health covid-19 database notifications and list of medications taken regularly for more than 8 weeks before the diagnosis of COVID-19 pneumonia from the national pharmacy database. Information about other systemic diseases and major medical conditions of patients will be procured from the medical histories gained by relevant physicians. Patient taking each drug group will be compared to those not taking that drugs in terms of clinical and demographical features mentioned above. Statistical analysis will be performed by using SPSS software.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: May 8, 2020
• Est. primary completion date: May 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Covid-19 pneumonia at least with typical infiltration on CT +/- positive PCR.

Exclusion Criteria:

• no typical infiltration and negative PCR results.

• not newly diagnosed.

Related Conditions & MeSH terms

• Covid-19
• Pneumonia

Intervention

Drug:
• ACE Inhibitors and Calcium Channel Blockers
effect of drugs on patients with covid-19 pneumonia

Locations

Country	Name	City	State
Turkey	Vital Hospital	Bahcelievler	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Nisantasi University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	extend of lung involvement	number of segments involved on admission	1 week
Primary	oxygen saturation on admission	hypoxia	2 week